Anna Bystrup Jacobsen1, Hugh Bostock2, Hatice Tankisi1. 1. Department of Clinical Neurophysiology, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus C, Denmark. 2. Institute of Neurology, University College London, London, UK.
Abstract
INTRODUCTION: The objective of this study was to evaluate a recently developed motor unit number estimation (MUNE) method, MScanFit MUNE (MScan), as a measure of disease progression in amyotrophic lateral sclerosis (ALS) compared with compound muscle action potential (CMAP) amplitude and 2 traditional MUNE methods. METHODS: ALS patients were evaluated clinically using the ALS Functional Rating Scale-Revised (ALSFRS-R). MScan, multiple-point stimulation MUNE (MPS), and motor unit number index (MUNIX) were performed in the abductor pollicis brevis (APB) muscle at baseline (27 patients), 4 months (23 patients), and 8 months (16 patients). RESULTS: Of the 5 measures, MScan registered the largest decline (8.7% per month), compared with MPS (3.4%), MUNIX (4.8%), CMAP amplitude (2.0%), and ALSFRS-R (1.9%). Only MScan and ALSFRS-R registered significant decrements over 4 and 8 months. DISCUSSION: MScan may be useful as a sensitive, objective tool for quantifying motor unit loss in ALS. Muscle Nerve 59:82-87, 2019.
INTRODUCTION: The objective of this study was to evaluate a recently developed motor unit number estimation (MUNE) method, MScanFit MUNE (MScan), as a measure of disease progression in amyotrophic lateral sclerosis (ALS) compared with compound muscle action potential (CMAP) amplitude and 2 traditional MUNE methods. METHODS:ALSpatients were evaluated clinically using the ALS Functional Rating Scale-Revised (ALSFRS-R). MScan, multiple-point stimulation MUNE (MPS), and motor unit number index (MUNIX) were performed in the abductor pollicis brevis (APB) muscle at baseline (27 patients), 4 months (23 patients), and 8 months (16 patients). RESULTS: Of the 5 measures, MScan registered the largest decline (8.7% per month), compared with MPS (3.4%), MUNIX (4.8%), CMAP amplitude (2.0%), and ALSFRS-R (1.9%). Only MScan and ALSFRS-R registered significant decrements over 4 and 8 months. DISCUSSION: MScan may be useful as a sensitive, objective tool for quantifying motor unit loss in ALS. Muscle Nerve 59:82-87, 2019.
Keywords:
ALS Functional Rating Scale; MScan, motor unit loss; MUNE, motor unit number estimation; MUNIX, multiple-point stimulation; amyotrophic lateral sclerosis; follow-up study
Authors: Nick S Verber; Stephanie R Shepheard; Matilde Sassani; Harry E McDonough; Sophie A Moore; James J P Alix; Iain D Wilkinson; Tom M Jenkins; Pamela J Shaw Journal: Front Neurol Date: 2019-04-03 Impact factor: 4.003
Authors: Diederik J L Stikvoort García; Maria O Kovalchuk; H Stephan Goedee; Leonard J van Schelven; Leonard H van den Berg; Hessel Franssen; Boudewijn T H M Sleutjes Journal: Muscle Nerve Date: 2021-12-16 Impact factor: 3.852
Authors: Emilio Geijo-Barrientos; Carlos Pastore-Olmedo; Pedro De Mingo; Miguel Blanquer; Joaquín Gómez Espuch; Francisca Iniesta; Natalia García Iniesta; Ana García-Hernández; Carlos Martín-Estefanía; Laura Barrios; José M Moraleda; Salvador Martínez Journal: Front Neurosci Date: 2020-03-24 Impact factor: 4.677
Authors: Steve Vucic; Robert D Henderson; Susan Mathers; Merrilee Needham; David Schultz; Matthew C Kiernan Journal: Ann Clin Transl Neurol Date: 2021-09-03 Impact factor: 4.511